Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Ribeiro
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors C. Ribeiro1, J. Barreira2, A. Parmanande1, P. Semedo1, M. Semedo1, M. Silva1, N. Costa1, V. Ribeiro1, E. Coimbra1, E. Barroso1
  • 1CHLC, Lisboa, Portugal, /
  • 2CHLC, Lisbon, Portugal, /


In hepatocellular carcinoma (HCC), locoregional therapies are used to reduce tumor progression and decrease dropouts from the liver transplant (LT) waiting list. Evidence on the effectiveness of such bridge therapies to LT is scarce. Our aim is to explore the role of transarterial chemoembolization (TACE) as bridge therapy to LT for HCC.